Anavex life sciences announces attention-ad anavex®2-73 extension clinical study in early alzheimer’s disease

Anavex life sciences corp. announced the initiation of the attention-ad, a long-term extension study for patients with early alzheimer’s disease and treated with anavex®2-73 (blarcamesine). the attention-ad study (open label extension study for patients with early alzheimer’s disease (ad) enrolled in study anavex2-73-ad-004), which is an extension of the phase 2b/3 anavex®2-73-ad-004 clinical study currently underway, will give ad patients an opportunity to continue their treatment. this study is expected to last two years for patients included in the anavex®2-73-ad-004 study, once they have completed the placebo-controlled 48-week phase 2b/3 trial. all patients who participate in the phase 2b/3 anavex®2-73-ad-004 study will be eligible to participate also in the attention-ad study under a voluntary open label extension protocol.
AVXL Ratings Summary
AVXL Quant Ranking